SynthesisNeurobiology of aging2023
Investigation of the independent role of a rare APOE variant (L28P; APOE*4Pittsburgh) in late-onset Alzheimer disease.
Synthesis in Neurobiology of aging, 2023. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 15 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
15 citing papers in PubMed, 16 citations in OpenAlex.
- Lifespan exposure to hormone therapies and structural brain morphometry in older women.NeuroImage · 2026Trial
- Cognitive and Brain Reserve as Modifiers of Early Alzheimer Disease-Related Cognitive Vulnerability.Neurology · 2026Trial
- Recent advances in Alzheimer's disease: From molecular mechanisms to therapeutic strategies.Cell · 2026Review
- Greater choroid plexus volume is linked to poor sleep, neurodegeneration, and cognitive deficits in older adults: Evidence from the IGNITE Study.Alzheimer's & dementia : the journal of the Alzheimer's Association · 2026Article
- Evidence of APOE4-related brain vulnerabilities in verbal memory systems in midlife women.Alzheimer's & dementia : the journal of the Alzheimer's Association · 2026Article
- Physical activity, aerobic fitness, and AD blood biomarkers: The IGNITE study.Alzheimer's & dementia : the journal of the Alzheimer's Association · 2026Article
- Plasma biomarkers identify brain ATN abnormalities in a dementia-free population-based cohort.Alzheimer's research & therapy · 2025Article
- Search for the elusive haplotype of the APOE polymorphism associated with Alzheimer's disease.Scientific reports · 2025Article
- Blood biomarkers differentiate AD-related versus non-AD-related cognitive deficits.Alzheimer's & dementia : the journal of the Alzheimer's Association · 2025Article
- Impact of Apolipoprotein E Variants: A Review of Naturally Occurring Variants and Clinical Features.Journal of atherosclerosis and thrombosis · 2025Review
- Cardiorespiratory fitness is associated with cognitive function in late adulthood: baseline findings from the IGNITE study.British journal of sports medicine · 2025Article
- Lifetime estrogen exposure and domain-specific cognitive performance: results from the IGNITE study.Frontiers in aging neuroscience · 2025Article
- Understanding Cognitive Aging Through White Matter: A Fixel-Based Analysis.Human brain mapping · 2024Article
- Current insights into apolipoprotein E and the immune response in Alzheimer's disease.Immunological reviews · 2024Review
- Associations of endogenous estrogens, plasma Alzheimer's disease biomarkers, andFrontiers in aging neuroscience · 2024Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
12 authors at 2 institutions in 1 country.
Funding
Abstract
A rare missense APOE variant (L28P; APOE*4Pittsburgh), which is present only in populations with European ancestry, has been reported to be a risk factor for late-onset Alzheimer's disease (LOAD). However, due to the complete linkage disequilibrium of L28P with APOE*4 (C112R), its independent genetic association is uncertain. The original association study implicating L28P with LOAD risk was carried out in a relatively small sample size. In the current study, we have re-evaluated this association in a large case-control sample of 15,762 White U.S. subjects and investigated its independent effect in APOE 3/4 subjects, as L28P has been observed only in the heterozygous state of APOE*4 carriers and 3/4 is the most common genotype containing the APOE*4 allele. The heterozygous carrier frequency of L28P, all with APOE*4, was about 3-fold higher in AD cases than in cognitively intact controls (0.845% vs. 0.277%). The age- and sex-adjusted meta-analysis odds ratio (OR) was 2.87 (95% CI: 1.34 - 6.13; = 0.0066). Among APOE 3/4 subjects, age- and sex-adjusted meta-analysis OR was 1.53 (95% CI: 0.70 - 3.36; p = 0.28), indicating its effect was independent of APOE*4. The lack of statistical significance appears mainly due to the low power of 4138 subjects with the 3/4 genotype (12% power at α= 0.05) compared to the required sample of 139,088 subjects with the 3/4 genotype to detect an OR of 1.5 at α= 0.05 and 80% power. Our data suggesting that L28P has an independent genetic effect on AD risk is reinforced by earlier experimental findings showing that this mutation leads to significant structural and conformational changes in the ApoE4 molecule and can induce functional defects associated with neuronal Aβ42 accumulation and oxidative stress. Additional functional studies in cell-based systems and animal models will help to delineate its functional significance in the etiology of AD.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.